PSI Leads New Research To Fight Metastatic Prostate Cancer
PSI Leads New Research To Fight Metastatic Prostate Cancer Researchers at the Paul Scherrer Institute (ENS Corporate Member, PSI) are developing a new drug that could increase the survival chances of patients with metastatic prostate cancer. The drug, studied by a research consortium involving PSI, the University Hospital Basel and ETH Zurich, is now being…